Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial-Reference-Cited by-同舟云学术

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial

Published:2017-02-20 Issue:7 Volume:57 Page:906-917
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Shoaf Susan E.¹,Chapman Arlene B.²,Torres Vicente E.³,Ouyang John¹,Czerwiec Frank S.¹

Affiliation:

1. Otsuka Pharmaceutical Development & Commercialization; Rockville MD, USA

2. Division of Nephrology; Emory University School of Medicine; Atlanta GA, USA

3. Division of Nephrology and Hypertension; Mayo Clinic; Rochester MN, USA

Funder

Otsuka America Pharmaceutical

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.880/fullpdf

Reference21 articles.

1. Oral tolvaptan is safe and effective in chronic hyponatremia;Berl;J Am Soc Nephrol,2010

2. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia;Schrier;N Engl J Med,2006

3. Dissociation between urine osmolality and urinary excretion of aquaporin-2 in healthy volunteers;Baumgarten;Nephrol Dial Transplant,2000

4. Prediction of creatinine clearance from serum creatinine;Cockcroft;Nephron,1976

5. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study;Torres;Am J Kidney Dis,2011

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What is the Appropriate Dose of Tolvaptan in ADPKD?;Kidney International Reports;2024-04

2. Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD;Kidney International Reports;2024-04

3. Comparing Effects of Tolvaptan and Instruction to Increase Water Consumption in ADPKD: Post Hoc Analysis of TEMPO 3:4;Kidney360;2023-11-21

4. Immediate drop of urine osmolality upon tolvaptan initiation predicts impact on renal prognosis in patients with ADPKD;Nephrology Dialysis Transplantation;2023-11-03

5. Effects of salt and protein intake on polyuria in V2RA-treated ADPKD patients;Nephrology Dialysis Transplantation;2023-10-06